APR 1 8 200. SIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of: WEI et al.

Art Unit: 1632

Serial No.: 10/663,794

Examiner:

Filed: September 17, 2003

Atty. Docket: CL001164CIP-DIV II

For: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE

PROTEINS, AND USES THEREOF

Statement Regarding Duty to Disclose Information Material To Patentability Under 37 CFR 1.56 (a) and (b)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

No fee is due for this submission. However, the Patent and Trademark Office is authorized to charge any necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

Date: April 08, 2004

Justin D Karjala, Reg No. 43,704

Celera Genomics 45 West Gude Drive, C2-4#21 Rockville, MD 20850

Tel: 240-453-3812 Fax: 240-453-3084

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB Under the Paper ork Reduction control number.

Complete if Known Substitute for form 1449B/PTO 10/663,794 **Application Number** INFORMATION DISCLOSURE September 17, 2003 Filing Date Ming-Hui WEI et al STATEMENT BY APPLICANT **First Named Inventor** 1632 **Group Art Unit** (use as many sheets as necessary) **Examiner Name** of **Attorney Docket Number** Sheet 1 CL001164CIP-DIV II

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	72
er de Falen	,,,	Results of BLAST search of SEQ ID NO: 2 against Derwent (FastAlertP and GeneseqP) and NCBI (pataa) Protein Patent Databases on December 8, 2003.	
g v nak Wor, somither	Tree of the Control	te market en	property server, per people to
i ilizan eterritaria eterritaria. Se	. [()	garaganaga garaga ar	
- ಜನವಿತಿನಿ ಎಂ	s:2	Sees also and discount for the sees of the	
11 (2000)	. Budde		
?			
	a ren	Anna is it is and an enter a company of the second of the	
يما عيوك هاي سيوسي دان و يو	-		
	2441 9		
ماناند کا میکستان دورون	N	git. G. St. at agreen in ilemente somlanin 1 distant is distant à Merfell internatively. Never obsesse et feminent dem	
er r			
			لـــــــــــــــــــــــــــــــــــــ
Examine Signatur		Date Considered	
Sidilaini	<u> </u>	1 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.